Clinical Trial Update: Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating conversion therapy with FOLFOX-HAIC plus lenvatinib and tislelizumab for hepatocellular carcinoma with portal vein tumor thrombus; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Portal Vein Tumor Thrombosis

Drugs mentioned

• FOLFOX-HAIC
• LENVIMA (lenvatinib)
• Tyvyt (Sintilimab)

Snippet

Sponsor: First Hospital of China Medical University | Conditions: Hepatocellular Carcinoma (HCC), Portal Vein Tumor Thrombus | Phase 2 | Status: NOT_YET_RECRUITING